Short Communication | DOI: https://doi.org/10.31579/2578-8965/099
Allied Market Research, Viman Nagar Pune Sainik Nagar, Somnath Nagar, Wadgaon Sheri, Pune, Maharashtra, India.
*Corresponding Author: Ashish Gujrathi, Allied Market Research, Viman Nagar Pune Sainik Nagar, Somnath Nagar, Wadgaon Sheri, Pune, Maharashtra, India.
Citation: Ashish G.(2022) Women Health Awareness, Acquisitions, and Partnerships to Bring New Era for Contraceptive Drugs.. J. Obstetrics Gynecology and Reproductive Sciences 6(1) DOI:10.31579/2578-8965/099
Copyright: © 2022, Ashish Gujrathi, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 27 September 2021 | Accepted: 18 November 2021 | Published: 04 January 2022
Keywords: acquisitions; contraceptive drugs; estrogen; CRCAtm
The spread of COVID-19 and the resulted lockdown imposed across the globe has negatively affected the contraceptive drugs market. Many women across the world found it hard to purchase the pills as contraceptive drug manufacturers were facing challenges due to inconsistent supply chains and the workforce.
However, as the lockdown is getting lifted across the globe, the market is expected to gain traction. Due to the rise in online availability of contraceptive drugs, customers can have easy access to them, which works in favour of the market.
As the growth of the market is visible to many experts and many credible market research reports are expecting a positive future, the market is witnessing some trends such as partnerships, acquisitions, launching new drugs, research and development, and favorable government regulations.
As per the market research report published by Allied Market Research, the global contraceptive drugs market is anticipated to reach $24,412.22 million by 2027, manifesting a CAGR of 6.9% from 2020 to 2027.
As the lockdown has been lifted and online sale of contraceptives is gaining popularity, organizations are launching new techniques and platforms that help drug manufacturers develop cost-efficient and effective drugs.
Agilum Healthcare Intelligence has recently announced the official launch of CRCAtm, which is Comparative Rapid Cycle Analytics® P&T. It is a new-gen analytics platform developed for drugs manufacturing companies. It comes with robust functions and increases the processing speed.
It helps to check drug manufacturing cost and payment by the payer. It aids hospital pharmacies increase their drug use, improve results, and decline the total cost of medical care treatment.
Governments in developed countries such as Canada are passing favourable laws to help in boosting women's health. One such regulation was announced recently.
Nextstellis is a new birth control pill launched in the market for Canadian women. What makes this contraceptive pill different from others is that it is made using a plant-based estrogen. While most of the contraceptive pills in the market use ethinylestradiol, which is a synthetic Estrogen, Nextstellis uses estetrol (E4).
As per the claims made by Dr. Brian Hauck of Foothills Medical Centre, the pill does not affect the liver in the way a traditional pill does. The doctor says the research into E4 has been ongoing for years, and it has finally got approval from the Canadian regulatory body.
Canada is one of the earlier countries to provide regulatory approval and make it available in the market. Health Canada approved the drug for public use in March.
An acquisition is a common trend for a growing market. The contraceptive drugs market is not an exception to it.
A known contraceptive drugs manufacturer HRA Pharma is recently acquired by Perrigo Company plc. HRA is a leading global consumer self-care company and also one of the fastest-growing over-the-counter ("OTC") companies across the globe.
This acquisition will make Perrigo a global leader in consumer self-care and strengthen its presence in the high-potential European region. It also helps Perrigo to extend its offerings with the help of brands such as a trusted OTC brand Compeed®,an OTC emergency contraception brand ellaOne®, and the OTC scar care brand Mederma®. HRA Pharma is an emergency contraception leader in the European region.
Dear Editorial Team, Clinical Medical Reviews and Reports. My experience with the journal was highly positive. The peer-review process was rigorous, constructive, and completed in a timely manner. The reviewers provided valuable comments that helped improve the quality and clarity of our manuscript. The editorial office was professional, responsive, and supportive throughout all stages of the publication process. Communication was clear and efficient, and any questions were addressed promptly. Overall, I found the journal to maintain high scientific standards and an excellent publication workflow. I would be pleased to consider submitting future work to this journal. Best wishes from, Elena Popa.
It was my pleasure to submit my testimonial concerning the Reviewer Board of our Scientific Journal “Brain and Neurological Disorders”. The Reviewers focused on some modifications and their contribution was helpful. The ladies of our Editorial Office were also supported my efforts. It was my honor to have such a co-operation and I am looking forward for more collaboration.
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Thank you for the speedy and efficient peer review process. I appreciate the fact that your peer reviewers do not take months to respond like with some other journals. I would also like to thank the editorial office for responding quickly to my questions. It is an excellent journal. I plan to submit more manuscripts in the future. Best wishes from, Robert W. McGee
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Working with you and your team on our recent publication in JCRR has been a truly wonderful and enjoyable experience. The responses were prompt, and the reviewers were patient, constructive, and highly professional. One reviewer in particular gave me the feeling that a professor was carefully reading and commenting on my coursework, which was deeply touching. The entire process was straightforward and hassle‑free, with no tedious online forms to complete. I highly recommend this journal. Best wishes from, DR Aibing Rao, Head of R&D
I Appreciate the Opportunity to Share my Experience with the Journal of Clinical Research and Reports. The peer review process was timely and constructive, and the feedback provided helped improve the quality of our manuscript. The editorial office was professional, responsive, and supportive throughout the process, ensuring smooth communication and efficient handling of the submission. Overall, it was a positive experience collaborating with your team.
Dear Mercy Grace, Editorial Coordinator of Obstetrics Gynecology and Reproductive Sciences, We would like to express our gratitude for your help at all stages of publishing and editing the article. The editors of the magazine answer all the necessary questions and help at every stage. We will definitely continue to cooperate and publish other works in the Obstetrics Gynecology and Reproductive Sciences! Best wishes from, Alla Konstantinovna Politova,
